Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.34 |
| ▸ | BTN3A1 | O00481 | 3/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | ELANE | P08246 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4268814 | 0.83 | ELANE (0.40) | ALDH1A1HTTKDM4EELANE | |
| SCHEMBL1811808 | 0.77 | RAB9A (0.46) | ALDH1A1HTTKDM4EL3MBTL1HPGD | |
| SCHEMBL441596 | 0.74 | KCNN4 (0.42) | SRCALDH1A1PKMHTTKCNN4 | |
| SCHEMBL7032414 | 0.73 | BTN3A1 (0.42) | SRCPKMHTTL3MBTL1BTN3A1 | |
| SCHEMBL5996997 | 0.72 | BTN3A1 (0.40) | SRCPKMHTTLMNAL3MBTL1 | |
| SCHEMBL643837 | 0.72 | BTN3A1 (0.40) | SRCPKMHTTLMNAL3MBTL1 | |
| SCHEMBL2012770 | 0.70 | ELANE (0.40) | SRCALDH1A1PKMHTTKDM4E | |
| SCHEMBL2012767 | 0.70 | ELANE (0.40) | SRCALDH1A1PKMHTTKDM4E | |
| SCHEMBL17902756 | 0.70 | SRC (0.44) | SRCALDH1A1PKMHTTKDM4E | |
| SCHEMBL11433980 | 0.69 | SRC (0.50) | SRCALDH1A1PKMHTTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1235833-B1 | ANALOGS OF (1S, CIS)-4-(2-AMINO-9H-PURIN-9-YL)-2-CYCLOPENTENE-1-METHANOL AS ANTIVIRAL | GLAXO GROUP LTD (GB) | 2004-02-25 | — | — | EP | disclosed |
| US-20030040506-A1 | Analogs of (1s,cis)-4-(2-amino-9h-purin -9-yl) -2-Cyclopentene-1-methanol as antiviral | SMITHKLINE BEECHAM CORPORATION | 2003-02-27 | — | — | US | disclosed |
| EP-1235833-A1 | ANALOGS OF (1S, CIS)-4-(2-AMINO-9H-PURIN-9-YL)-2-CYCLOPENTENE-1-METHANOL AS ANTIVIRAL | GLAXO GROUP LIMITED (GB) | 2002-09-04 | — | — | EP | disclosed |
| WO-2001042256-A1 | ANALOGS OF (1S, cis)-4-(2-AMINO-9H-PURIN-9-YL)-2-CYCLOPENTENE-1-METHANOL AS ANTIVIRAL | GLAXO GROUP LIMITED (GB) | 2001-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030040506-A1 | Analogs of (1s,cis)-4-(2-amino-9h-purin -9-yl) -2-Cyclopentene-1-methanol as antiviral | MAVS, ZC3HAV1, HAVCR2 | SRC 3486/4885ALDH1A1 510/4885PKM 4107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.